Bayer to Present New Data from Hematology and Oncology Portfolios at ASH 2015 Annual Meeting

WHIPPANY, N.J., Nov. 30, 2015 /PRNewswire/ -- Bayer will present the latest preclinical and clinical data from its hematology and oncology development pipeline at the American Society of Hematology (ASH) 57th Annual Meeting, December 5-8, 2015, in Orlando, FL. In total, eleven abstracts have been accepted for poster presentations, demonstrating Bayer's ongoing commitment to new research to benefit patients.

"We are excited to present the latest data from our expanding hematology and oncology pipelines, as they demonstrate our scientific leadership in bleeding disorders and cancer research," said David Weinreich, M.D., Bayer's head of global development for Specialty Medicine.

The hematology pipeline at Bayer includes compounds in various stages of development for hemophilia, sickle cell anemia, thalassemia and other blood and bleeding disorders. The oncology franchise at Bayer now includes three marketed products and several other compounds in various stages of clinical development. Together, these portfolios and pipelines reflect the company's commitment to delivering science for a better life, prioritizing specific targets for intervention with the potential to improve the way that cancer and rare blood and bleeding disorders are treated.

The following studies will be presented at ASH 2015:

Hemophilia:
Analysis from BAY 81-8973 Studies

• New Approach in Assessing the Pharmacokinetic/Pharmacodynamic Relationship in Patients With Severe Hemophilia A Using Data From BAY 81-8973 Studies
  • Abstract #1095, Session: 322. Disorders of Coagulation or Fibrinolysis: Poster I
  • Saturday, December 5, 2015, 5:30 PM-7:30 PM; Orange County Convention Center, Hall A, Level 2 

• Patterns of prior treatment and bleeds among patients with severe hemophilia A: Impact on frequency of dosing with Bay 81-8973 in the LEOPOLD I trial
  • Abstract #1103, Session: 322. Disorders of Coagulation or Fibrinolysis: Poster I
  • Saturday, December 5, 2015, 5:30 PM-7:30 PM; Orange County Convention Center, Hall A, Level 2

• BAY 81-8973, a Full-Length Recombinant Factor VIII: Results From Assay Field Study
  • Abstract #3539, Session: 322. Disorders of Coagulation or Fibrinolysis: Poster III
  • Monday, December 7, 2015, 6:00 PM-8:00 PM; Orange County Convention Center, Hall A, Level 2

BAY 1093884 Studies

• Acute Efficacy of a Novel Anti-Tissue Factor Pathway Inhibitor Antibody BAY 1093884 in Hemophilia A Mouse Severe Tail Bleeding
  • Abstract #3500, Session: 321. Blood Coagulation and Fibrinolytic Factors: Poster III
  • Monday, December 7, 2015, 6:00 PM-8:00 PM; Orange County Convention Center, Hall A, Level 2

• Antibody Engineering of Anti-TFPI Bypass Therapeutic BAY 1093884: Isotype Selection and Sequence Optimization
  • Abstract #3496, Session: 321. Blood Coagulation and Fibrinolytic Factors: Poster III
  • Monday, December 7, 2015, 6:00 PM-8:00 PM; Orange County Convention Center, Hall A, Level 2

Other Studies

• A Factor VIII with Site-Specific Pegylation Attenuates the Binding with Inhibitors Results in the Retention of Hemostatic Effect
  • Abstract #1076, Session: 321. Blood Coagulation and Fibrinolytic Factors: Poster I (61 abstracts)
  • Saturday, December 5, 2015, 5:30 PM-7:30 PM; Orange County Convention Center, Hall A, Level 2

• Renal Status and Hematuria in Older Patients with Hemophilia
  • Abstract #2290, Session: 322. Disorders of Coagulation or Fibrinolysis: Poster II
  • Sunday, December 6, 2015, 6:00 PM-8:00 PM; Orange County Convention Center, Hall A, Level 2

• Mapping T-Cell Peptide Epitopes on Activated Recombinant Factor VII (rFVIIa) Contributing to Inhibitor Antibody Response
  • Abstract #2295, Session: 322. Disorders of Coagulation or Fibrinolysis: Poster II
  • Sunday, December 6, 2015, 6:00 PM-8:00 PM; Orange County Convention Center, Hall A, Level 2

• Characterization of a High-Affinity Fully Human IgG2 Antibody Against Tissue Factor Pathway Inhibitor As a Bypass Agent for the Treatment of Hemophilia
  • Abstract #3513, Session: 322. Disorders of Coagulation or Fibrinolysis: Poster III
  • Monday, December 7, 2015, 6:00 PM-8:00 PM; Orange County Convention Center, Hall A, Level 2

• Protection of Microvascular Liver Perfusion With 5-Hydroxymethylfurfural in Sickle Cell Disease Mice Following Hypoxia-Induced Vasoocclusion
  • Abstract #3382, Session: 113. Hemoglobinopathies, Excluding Thalassemia – Basic and Translational Science: Poster III
  • Monday, December 7, 2015, 6:00 PM-8:00 PM; Orange County Convention Center, Hall A, Level 2

Oncology:
One abstract on copanlisib in a subset of patients from the completed Part A of a Phase II Study will be presented.  Part B, an extension of this Phase II Study in relapsed, refractory indolent non-Hodgkin's lymphoma (NHL), is currently ongoing (CHRONOS-1). Copanlisib is a pan-Class I phosphatidylinositol-3-kinase (PI3K) inhibitor with predominant inhibitory activity against both PI3K-alpha and PI3K-delta isoforms.

Copanlisib Phase IIa Study Subset

• Results of the Mantle Cell Lymphoma Subset from a Phase 2a Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent and Aggressive Lymphoma
  • Abstract #3935, Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster III
  • Monday, December 7, 2015, 6:00 PM-8:00 PM; Orange County Convention Center, Hall A, Level 2

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their lives. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed around 119,000 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.

Bayer® and the Bayer Cross® are registered trademarks of Bayer.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

SOURCE Bayer Corporation

Related Links

http://www.bayer.com